DeepMed Research

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

Not yet recruiting

Conditions: Risk Factor
Distant Metastasis
Cervical Cancer
Radiotherapy
Prognostic Model

Interventions: Radiation: external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)

First Posted Date: 2023-10-26

Last Posted Date: 2023-10-26

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 500

Registration Number: NCT06101966

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma by AJCC V8 Stage

Interventions: Radiation: New-mode reduce-volume target IMRT

First Posted Date: 2023-10-23

Last Posted Date: 2025-03-13

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 474

Registration Number: NCT06095154

Locations: 🇨🇳
Fujian Cancer hospital, Fuzhou, Fujian, China

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Phase 3

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: without concurrent cisplatin chemotherapy
Drug: with concurrent cisplatin chemotherapy

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 476

Registration Number: NCT06095167

Locations: 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: CVL218

First Posted Date: 2023-10-12

Last Posted Date: 2023-10-12

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 96

Registration Number: NCT06078670

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer
Endometrial Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2023-10-04

Last Posted Date: 2024-01-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 45

Registration Number: NCT06066216

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Not Applicable

Recruiting

Conditions: Stage IIIA Hepatocellular Carcinoma

Interventions: Combination Product: Radiotherapy combined with TKI and Anti-PD-1 Antibody

First Posted Date: 2023-09-29

Last Posted Date: 2024-04-12

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 22

Registration Number: NCT06061445

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer

Not yet recruiting

Conditions: Cervix Carcinoma

Interventions: Other: no intervention

First Posted Date: 2023-09-15

Last Posted Date: 2023-09-26

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT06039982

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Eribulin-Based Regimen
Drug: nab-paclitaxel based regimen
Drug: Other Chemotherapy Regimen

First Posted Date: 2023-07-20

Last Posted Date: 2023-07-20

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT05953909

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Phase 1

Conditions: Malignant Melanomas

Interventions: Drug: Recombinant Human Adenovirus Type 5 Injection

First Posted Date: 2023-07-03

Last Posted Date: 2023-07-10

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 10

Registration Number: NCT05928962

Locations: 🇨🇳
Fujian Cancer Hospital, Department of Internal Medicine, Ward 19, Fuzhou, Fujian, China

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Phase 1

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: XH-30002 capsule
Drug: Afatiinb tablet

First Posted Date: 2023-07-03

Last Posted Date: 2023-07-03

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05927844

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy